New pill shows promise against tough lung cancer mutations
NCT ID NCT06956001
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study tests a new daily pill, firmonertinib, against standard chemotherapy for people with advanced non-small cell lung cancer that has certain EGFR mutations (PACC or L861Q). About 300 participants will be randomly assigned to receive either the pill or chemo. The goal is to see if the pill can delay cancer growth and improve quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ethics Committee of cancer hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Email: •••••@•••••
-
Shandong Tumor Hospital
RECRUITINGShandong, Jinan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?
- Can a Two-Drug combo outsmart tough lung cancer?
- Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Drug duo aims to tackle tough lung cancers after first treatment fails
- Blood test may let cancer patients take safe breaks from immunotherapy